ArticleScientific reports2025
Unveiling the causative role of promoter variant rs113823671 in MMP7 in gallbladder cancer susceptibility.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder cancer (GBC) poses a significant global health threat, claiming 89,031 lives worldwide in 2022. This malignancy exhibits distinct genetic susceptibility patterns among populations, coupled with its aggressive nature and dismal prognosis. Among the factors implicated in cancer progression, Matrix Metalloproteinase 7 (MMP7) has emerged as a crucial biomarker due to its dual role in cancer causation and progression, but its role in GBC is completely unexplored. We hypothesized that promoter SNPs could modulate MMP7 expression, thus impacting GBC susceptibility. Our study aimed to assess the aberrant expression levels and genetic polymorphisms of MMP7 as potential risk factors for GBC. Initial screening of MMP7 promoter polymorphisms in a cohort of fifty GBC patients and controls using Sanger sequencing was followed by validation in a larger sample set comprising 300 GBC cases and 300 controls. Additionally, MMP7 protein expression was examined through immunohistochemistry in GBC tissue samples. Functional analysis of identified risk variants was carried out using luciferase reporter assays and in vitro promoter analysis in two cell lines to elucidate their impact on gene expression. MMP7 promoter variants, rs113823671 A > C (p-value = 0.034) and rs17098318 G > A (p-value = 0.024), exhibited significant associations with GBC. Reporter assays in two cell lines indicated that carriers of the risk allele 'A' at rs113823671 exhibited increased luciferase reporter activity, whereas no significant reporter activity was observed at rs17098318. MMP7 expression levels were markedly elevated in GBC compared to adjacent uninvolved normal tissue. Furthermore, genotype-phenotype analysis in tissue samples revealed that risk allele carriers exhibited higher MMP7 expression levels, with the correlation aligning with genetic association models. In conclusion, our study unveils the association of two novel MMP7 promoter risk variants, rs113823671, and rs17098318, with GBC and their role in GBC pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.